<DOC>
	<DOCNO>NCT02376075</DOCNO>
	<brief_summary>A recent study DPP-IV inhibitor Linagliptin show improvement urinary albumin creatinine ratio patient diabetic nephropathy . Gutzwiller et . Al . show GLP-1 increase renal Na secretion inhibit renal H secretion , indicate direct renal effect GLP-1 . Therefore , seem likely treatment DPP-IV inhibitor Linagliptin evolve several beneficial effect microvascular endothelial function beyond glucose control probably impact progression renal retinal microvascular disease . The objective trial investigate effect Linagliptin comparison placebo UACR patient high blood pressure increase albumin excretion . Numerous , equivalent endothelial , renal , retinal parameter serve objective study . All study parameter handle exploratory sense generation model discuss role DPP-IV inhibition renal retinal physiology .</brief_summary>
	<brief_title>Effects Linagliptin Endothelial- , Renal- , Retinal Function Patients With Hypertension Albuminuria</brief_title>
	<detailed_description>Renal tissue damage increase albumin excretion rate strong predictor development progression endothelial dysfunction development microvascular and/or macrovascular complication . Increased blood pressure well increase glucose level find impair renal- retinal function , close association incidence progression rate retinopathy nephropathy could observe . Endothelial dysfunction alteration microvascular blood flow early pathogenetic feature development renal retinal tissue damage find patient arterial hypertension / diabetes mellitus . A couple study show urinary albumin excretion associate morphological functional alteration retinal microvascular blood flow . In patient arterial hypertension blood pressure lower treatment show decrease albumin excretion rate improve endothelial function retinal vasculature . Recently DPP-IV Inhibitors introduce treatment type 2 diabetes mellitus . Beside metabolic effect drug class , several pleiotropic effect beyond metabolic control document numerous study , topic ongoing clinical research . Treatment DPP-IV inhibitor find improve myocardial endothelial function , improve blood lipid , low blood pressure improve marker renal function . GLP-1 receptor vessel , kidney heart might account glucose independent effect GLP-1 . However , also conceivable DPP-IV inhibition might exert vascular effect independent GLP-1 . In vitro study demonstrate DPP-IV express endothelial cell , inhibition DPP-IV reduce microvascular tone direct mediation nitric oxide system . Therefore , seem conceivable glucose independent effect DPP-IV inhibition might mediate GLP-1 receptor signal /or direct inhibition enzyme DPP-IV vascular , renal , retinal cell . A recent study DPP-IV inhibitor Linagliptin show improvement urinary albumin creatinine ratio patient diabetic nephropathy . Gutzwiller et . Al . show GLP-1 increase renal Na secretion inhibit renal H secretion , indicate direct renal effect GLP-1 . Therefore , seem likely treatment DPP-IV inhibitor Linagliptin evolve several beneficial effect microvascular endothelial function beyond glucose control probably impact progression renal retinal microvascular disease . The objective trial investigate effect Linagliptin comparison placebo UACR patient high blood pressure increase albumin excretion . Numerous , equivalent endothelial , renal , retinal parameter serve objective study . All study parameter handle exploratory sense generation model discuss role DPP-IV inhibition renal retinal physiology .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patient sign date write informed consent participate trial Arterial hypertension Stable antihypertensive treatment within last 3 month Age ≥ 45 ≤ 80 year Micro macroalbuminuria define UACR morning urine &gt; 20 mg/g female &gt; 30 mg/g male and/or arterial hypertension 5 year currently treat two antihypertensive drug control blood pressure history cardiovascular disease stroke . Patient consent his/her family physician inform trial participation History type 1 diabetes History type 2 diabetes Uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) Acute infection Any history glomerulonephritis Any kidney disease cause hypertension judge Investigator Glomerular filtration rate ( GFR ) &lt; 30 ml/min ( estimate use Modification Diet Renal Disease ( MDRD ) formula ) Medical history hypersensitivity study drug drug similar chemical structure History severe multiple allergy Treatment investigational drug within 3 month trial entry Progressive fatal disease History drug alcohol abuse past 2 year Condition kidney transplantation Serum potassium &gt; 5.5 mmol/L Pregnancy breast feed Sexually active woman childbearing age practice highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , sexual abstinence vasectomise partner . Acute myocardial infarction , open heart surgery cerebral event ( stroke/TIA ) within previous 3 month Any elective surgery study participation Uncontrolled unstable angina pectoris Intake Coumarin coumarin derive compound phenprocoumon ( Marcumar ) warfarin ( Coumadin , Warfant ) Intake rifampicin carbamazepine HbA1c ≥ 6,5 % A Body Mass Index &gt; 35 kg/m² CHF NYHA stage III IV</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>